NC’s BioCryst Pharmaceuticals gets another boost with FDA fast-track designation


After securing a place in a European program designed to accelerate the process of getting medicines to patients, BioCryst Pharmaceuticals has landed a spot in a similar U.S. program.

Previous In crucial win, bluebird nabs a second FDA committee endorsement
Next How linking social services with medical care improves Oregon’s health equity